back to top
Search
HomeTagsTreatment

Treatment

Market

ALK licenses rights to neffy ®, the primary accredited adrenaline nasal spray for emergency therapy of allergic reactions (anaphylaxis) By Investing.com

ALK (ALKB:DC / OMX: ALK B) right now introduced that it has entered right into a strategic license settlement with US-based ARS Prescribed drugs,...
-
Blockchain

SHOCK VITALIZE-MEGA Makes Ache Reduction Accessible with Its ESWT Therapy – Blockchain Information Web site

China, sixth Nov 2024, Grand Newswire – SHOCK VITALIZE-MEGA is thrilled to launch their superior Extracorporeal Shock Wave Remedy (ESWT) machine. ESWP is a...
-
Blockchain

Totalcare Dental and Dermal Presents Specialised Enamel Grinding Therapy in Sydney – Blockchain Information Web site

Australia, twenty second Oct 2024, – Totalcare Dental and Dermal has launched a brand new therapy for enamel grinding, also referred to as...
-
Blockchain

Align Well being Collective Now Presents Corns and Callus Therapy in South Brisbane Podiatry Clinic – Blockchain Information Web site

Australia, 18th Oct 2024, – Align Well being Collective, a number one supplier of podiatry providers in South Brisbane, has expanded its choices...
-
Blockchain

Radiant Smiles Dental Care Introduces Specialised Remedy for Anxious Kids in Perth – Blockchain Information Web site

Australia, seventeenth Oct 2024, – Radiant Smiles Dental Care, based mostly in Perth, has introduced the launch of a brand new specialised remedy...
-
Market

Registrational Section III Research of APG-2449 Cleared by China CDE for the Remedy of Sufferers with NSCLC By Investing.com

ROCKVILLE, Md. and SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a world biopharmaceutical firm engaged in discovering, growing and commercializing therapies...
-
Market

Rallybio shares maintain Purchase score on HPP therapy information By Investing.com

On Tuesday, H.C. Wainwright maintained a Purchase score on Rallybio Corp. (NASDAQ:RLYB) shares with a gentle worth goal of $6.00. The endorsement follows Rallybio's...
-
Market

Akeso Printed Ivonescimab plus Ligufalimab as First-Line Remedy for PD-L1-Constructive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 By Investing.com

Head-to-Head Section 3 Trial In comparison with Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ -- On the 2024 European Society for Medical Oncology (ESMO)...
-
Load more

Most Popular

spot_img

our mission is to demystify the complex world of cryptocurrencies and make it accessible to everyone, from beginners to seasoned investors.

2024 DailyMooj. All Rights Reserved.

Latest articles

Popular Categories

2024 DailyMooj. All Rights Reserved.